One of the main drivers within the field of bottom-up synthetic biology is to develop artificial chemical machines, perhaps even living systems, that have programmable functionality. Bottom-up methods take an engineering approach to biology, with multiple downstream applications. Such applications that require very specific quantities of product e.g., antibodies, drug, or vaccines, necessitate the design of
vesicles with total and precise control of a vesicleβs molecular machinery.
There exists a wide range of toolkits to produce and engineer artificial cells with an ever-increasing array of functionality and capability. However, little attention has been given to the quality control of vesicle production; so, to date, there is a paucity of techniques that are able to measure their molecular constituents precisely upon formation and with absolute quantification. The work outlined here presents the
development of a microfluidic-based methodology that is able to characterise artificial cells at the single vesicle level with single-molecule resolution.
High content fluorescence microscopy was used to assess the properties of Giant unilamellar vesicles (GUVs) and their statistics at the population level. Since this technique is semi-quantitative, the relative concentration of protein across the GUV population was determined however the absolute concentration of protein within each GUV was not.
To overcome this, a lab-on-a-chip approach was taken to determine the precise number of biomolecules within each GUV and across the population of GUVs. The pulldown-5
array single-molecule high-throughput (PASH) chip was developed and capable of determining the encapsulation efficiency of protein within GUVs produced by phase transfer of an inverted emulsion. Using this approach, it was possible to determine the variability of the encapsulation efficiency between GUVs across a population as well as between different populations while testing batch-to-batch variation. The encapsulation efficiency measured to be 11.4 Β± 6.2% across all tested parameters. This has consequences for the use of GUVs as precise biological models as well as for their development in a variety of biotherapeutic applications.
To determine whether GUVs with specific concentrations of biomolecules could be produced by phase transfer, changes in the concentration of the seeding materials and reagents were investigated;
while inefficiencies in encapsulation could be overcome, the variation in concentration could not. The results presented in this thesis help to understand the limitation of the phase transfer technique applied to systems biology research. In biological systems, measuring changes in gene expression at the transcriptomic and proteomic level is important.
When used to develop simplified models of protein expression, these results indicate that vesicles produced using phase transfer may only be confidently used to produce 10-fold changes in encapsulant protein. It is possible to distinguish different GUV populations with a precision down to a two-fold change in encapsulant protein but with significant population overlap. The understanding of the limitations of encapsulation efficiency provides insight into the potential relevance of such systems for a variety of therapeutic applications such as smart drug delivery.Open Acces
